Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening: Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
The purpose of this study is to determine the effectiveness of progesterone given by mouth for minimizing drug EKG response to a drug.
Our objective is to evaluate and compare the efficacy of novel therapeutic approaches to reduce the risk of drug-induced QTc interval prolongation and TdP.
Participants will be paid for their participation.
- IRB Number: 1806935117
- Research Study Identifier: TX9173
- Principal Investigator: James Tisdale
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required